Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 112,500 |
5 mg | 在庫あり | ¥ 245,500 |
10 mg | 在庫あり | ¥ 298,500 |
25 mg | 在庫あり | ¥ 393,500 |
50 mg | 在庫あり | ¥ 500,500 |
100 mg | 在庫あり | ¥ 643,000 |
説明 | Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization. |
In vivo | In the alkali burn model, Befetupitant, a highly selective NK1R antagonist, was tested. Hemangiogenesis and lymphangiogenesis were effectively reduced (P<0.05) after topical application of Befetupitant for 4 days at both concentrations (0.4 and 1.6 mg/mL). However, both Befetupitant and its vehicle DMSO induced corneal opacity even in healthy controls, as observed during slit-lamp examination. Furthermore, fluorescein and hematoxylin-eosin staining confirmed DMSO toxicity by revealing epithelial damage and inflammatory cellular infiltration in the stroma. Despite Befetupitant's effectiveness in reducing corneal neovascularization (CNV) in the alkali burn model, its toxicity due to the DMSO vehicle led to the decision not to test it in the suture model[1]. |
別名 | Ro67-5930 |
分子量 | 565.55 |
分子式 | C29H29F6N3O2 |
CAS No. | 290296-68-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.88 mg/mL (12.16 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Befetupitant 290296-68-3 GPCR/G Protein Neuroscience Neurokinin receptor Ro67-5930 Inhibitor inhibitor inhibit